Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joergen Rungby

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ageing Research Reviews|June 28, 2008
On high-frequency insulin oscillationsOle Schmitz, Joergen Rungby, Linda Edge, et al.
Diabetes Care|May 1, 2007
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditionsAndrea Mari, Kristine Degn, Birgitte Brock, et al.
Clinical Endocrinology|December 20, 2008
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjectsSusanne Lerche, Liselotte Soendergaard, Joergen Rungby, et al.
Diabetes|April 28, 2004
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetesKristine B Degn, Claus B Juhl, Jeppe Sturis, et al.
Journal of Patient Safety|March 6, 2015
Medication Review and Patient Outcomes in an Orthopedic Department: A Randomized Controlled StudyMarianne Lisby, Dorthe Krogsgaard Bonnerup, Birgitte Brock, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ageing Research Reviews|June 28, 2008
On high-frequency insulin oscillationsOle Schmitz, Joergen Rungby, Linda Edge, et al.
Diabetes Care|May 1, 2007
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditionsAndrea Mari, Kristine Degn, Birgitte Brock, et al.
Clinical Endocrinology|December 20, 2008
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjectsSusanne Lerche, Liselotte Soendergaard, Joergen Rungby, et al.
Diabetes|April 28, 2004
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetesKristine B Degn, Claus B Juhl, Jeppe Sturis, et al.
Journal of Patient Safety|March 6, 2015
Medication Review and Patient Outcomes in an Orthopedic Department: A Randomized Controlled StudyMarianne Lisby, Dorthe Krogsgaard Bonnerup, Birgitte Brock, et al.
Pageof 1